We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NRC Health Trades at a Discount: Should You Buy, Sell or Hold?
Read MoreHide Full Article
From a valuation perspective, NRC Health (NRC - Free Report) stock looks attractive. NRC is currently trading at a trailing 12-month enterprise value/sales (EV/sales) of 3.77X, a roughly 35% discount compared with the industry average of 5.84X. NRC also trades at a lower valuation compared to other industry players, such as Experian plc (EXPGY - Free Report) and Iron Mountain Incorporated (IRM - Free Report) . Currently, EXPGY and IRM have EV/sales multiples of 4.28X and 6.62X, respectively.
Though NRC’s cheap valuation may present a potentially profitable opportunity for investors seeking value, a more comprehensive analysis is needed to determine if its discounted valuation is justified based on its fundamentals and growth prospects.
Image Source: Zacks Investment Research
NRC Stock’s Price Performance
NRC’s shares have surged 53.3% in the past year against the industry’s 14.9% decline. It has also outperformed Experian and Iron Mountain. Shares of Experian declined 30.3%, while Iron Mountain stock gained 11% in the same time frame.
Image Source: Zacks Investment Research
Business Tailwinds for NRC
NRC Health continues to benefit from a largely subscription-based revenue model, with revenue recognized over time reaching $66.1 million in the first half of 2026 versus $62.3 million a year earlier. Total recurring contract value also increased year over year, supported by sales to both new and existing customers. Management views TRCV as a leading indicator of future revenue trends, suggesting that sustained contract growth could translate into higher reported revenue in subsequent periods. Remaining contract revenue of about $188.3 million at June 30, 2026, including $44.8 million expected in the rest of 2026, adds further visibility.
Management highlighted broad-based commercial momentum, with Experience TRCV up in the mid-teens, Market Insights growing at a strong pace and the Governance Institute expanding nearly 10% year over year. The sales pipeline was described as up about 60% from the same quarter last year, while average deal size was also higher. NRC is also targeting cross-selling within its installed base, where roughly 70% of customers currently buy only one product. Greater connectivity across Experience, Insights and Governance solutions could deepen customer relationships, support multi-solution adoption and further expand wallet share over time.
NRC is continuing to invest in technology and product development, including AI-enabled capabilities such as ambient listening within its rounding solution. Management said these tools are designed to reduce manual transcription, organize conversations into summaries, identify service-recovery opportunities and surface real-time insights.
Management expects margin improvement as revenue growth catches up with recent investment spending and certain implementation costs normalize. Adjusted EBITDA margin was 27% in the second quarter, and the company expects the third-quarter margin to remain around the same level as the first half before further improvement into the fourth quarter. Liquidity also provides room to fund growth initiatives, with $3.3 million of cash, $17 million of unused revolver capacity and $27.6 million available under the delayed-draw term loan as of June 30, 2026. Operating cash flow also improved year over year in the first half of 2026, supporting financial flexibility.
Headwinds for NRC’s Business
NRC Health’s selling, general and administrative expenses remained high due to higher stock-based compensation, executive salaries and software costs, while continued technology investment contributed to a decline in operating income in the first half of 2026. Higher long-term debt also increased interest expense, and the company carried a $12.2 million working-capital deficit as of June 30, 2026. Revenue growth was partly offset by about $0.7 million of contra-revenue tied to third-party solutions, while management also noted buyer uncertainty following industry consolidation and expects implementation-related spending to continue before margins improve.
Conclusion
Overall, NRC Health is supported by recurring revenue growth, rising contract value, a stronger sales pipeline, cross-selling opportunities and continued product innovation, which could improve revenue visibility and support margin expansion over time. However, elevated operating expenses, ongoing technology and implementation spending, higher interest costs and a working-capital deficit remain notable risks.
NRC’s undervaluation, despite the rise in share price, presents a lucrative opportunity for investors to add the stock to their portfolio.
View the Zacks #1 Rank List
Image: Bigstock
NRC Health Trades at a Discount: Should You Buy, Sell or Hold?
From a valuation perspective, NRC Health (NRC - Free Report) stock looks attractive. NRC is currently trading at a trailing 12-month enterprise value/sales (EV/sales) of 3.77X, a roughly 35% discount compared with the industry average of 5.84X. NRC also trades at a lower valuation compared to other industry players, such as Experian plc (EXPGY - Free Report) and Iron Mountain Incorporated (IRM - Free Report) . Currently, EXPGY and IRM have EV/sales multiples of 4.28X and 6.62X, respectively.
Though NRC’s cheap valuation may present a potentially profitable opportunity for investors seeking value, a more comprehensive analysis is needed to determine if its discounted valuation is justified based on its fundamentals and growth prospects.
Image Source: Zacks Investment Research
NRC Stock’s Price Performance
NRC’s shares have surged 53.3% in the past year against the industry’s 14.9% decline. It has also outperformed Experian and Iron Mountain. Shares of Experian declined 30.3%, while Iron Mountain stock gained 11% in the same time frame.
Image Source: Zacks Investment Research
Business Tailwinds for NRC
NRC Health continues to benefit from a largely subscription-based revenue model, with revenue recognized over time reaching $66.1 million in the first half of 2026 versus $62.3 million a year earlier. Total recurring contract value also increased year over year, supported by sales to both new and existing customers. Management views TRCV as a leading indicator of future revenue trends, suggesting that sustained contract growth could translate into higher reported revenue in subsequent periods. Remaining contract revenue of about $188.3 million at June 30, 2026, including $44.8 million expected in the rest of 2026, adds further visibility.
Management highlighted broad-based commercial momentum, with Experience TRCV up in the mid-teens, Market Insights growing at a strong pace and the Governance Institute expanding nearly 10% year over year. The sales pipeline was described as up about 60% from the same quarter last year, while average deal size was also higher. NRC is also targeting cross-selling within its installed base, where roughly 70% of customers currently buy only one product. Greater connectivity across Experience, Insights and Governance solutions could deepen customer relationships, support multi-solution adoption and further expand wallet share over time.
NRC is continuing to invest in technology and product development, including AI-enabled capabilities such as ambient listening within its rounding solution. Management said these tools are designed to reduce manual transcription, organize conversations into summaries, identify service-recovery opportunities and surface real-time insights.
Management expects margin improvement as revenue growth catches up with recent investment spending and certain implementation costs normalize. Adjusted EBITDA margin was 27% in the second quarter, and the company expects the third-quarter margin to remain around the same level as the first half before further improvement into the fourth quarter. Liquidity also provides room to fund growth initiatives, with $3.3 million of cash, $17 million of unused revolver capacity and $27.6 million available under the delayed-draw term loan as of June 30, 2026. Operating cash flow also improved year over year in the first half of 2026, supporting financial flexibility.
Headwinds for NRC’s Business
NRC Health’s selling, general and administrative expenses remained high due to higher stock-based compensation, executive salaries and software costs, while continued technology investment contributed to a decline in operating income in the first half of 2026. Higher long-term debt also increased interest expense, and the company carried a $12.2 million working-capital deficit as of June 30, 2026. Revenue growth was partly offset by about $0.7 million of contra-revenue tied to third-party solutions, while management also noted buyer uncertainty following industry consolidation and expects implementation-related spending to continue before margins improve.
Conclusion
Overall, NRC Health is supported by recurring revenue growth, rising contract value, a stronger sales pipeline, cross-selling opportunities and continued product innovation, which could improve revenue visibility and support margin expansion over time. However, elevated operating expenses, ongoing technology and implementation spending, higher interest costs and a working-capital deficit remain notable risks.
NRC’s undervaluation, despite the rise in share price, presents a lucrative opportunity for investors to add the stock to their portfolio.